Ito Takafumi, Yorioka Noriaki
Section of Nephrology, Department of Internal Medicine, Faculty of Medicine, Shimane University, 85-1, Enya-cho, Izumo, 693-8501, Japan.
Department of Advanced Nephrology, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Clin Exp Nephrol. 2008 Aug;12(4):243-249. doi: 10.1007/s10157-008-0032-y. Epub 2008 Feb 15.
Continuous ambulatory peritoneal dialysis is a well-accepted treatment for end-stage renal disease, but its long-term success is limited. Peritoneal sclerosis is still one of the most important complications of long-term peritoneal dialysis and the low biocompatibility of peritoneal dialysis solutions plays a major role in the development of such sclerosis. In this review, we summarize recent experimental data about the biocompatibility of peritoneal dialysis solutions.
持续性非卧床腹膜透析是终末期肾病一种广泛接受的治疗方法，但其长期疗效有限。腹膜硬化仍是长期腹膜透析最重要的并发症之一，腹膜透析液的低生物相容性在这种硬化的发展中起主要作用。在本综述中，我们总结了关于腹膜透析液生物相容性的最新实验数据。
